Orforglipron: China Approves Lilly's Weight-Loss Pill

Is orforglipron approved in China?

Yes: China's National Medical Products Administration (NMPA) approved orforglipron on 12 November 2026 for long-term weight management in adults, Lilly China announced the same day ^[1]. The drug is sold in China under the brand name 穆优达 and was approved as a Class 1 innovative drug ^[1][2].

The approved use, according to Lilly's release, is weight management, on top of diet and exercise, in adults with obesity, or with overweight and at least one weight-related condition ^[1]. The Chinese business daily NBD reported that the NMPA's notice sets the threshold at an initial BMI of 30 kg/m² or above, or 27 to 30 with at least one weight-related comorbidity ^[2].

• First in China: Lilly says it is the first oral GLP-1 receptor agonist approved in China for adult weight management ^[1].
• Diabetes: an indication for adults with type 2 diabetes is still under review by the NMPA ^[1].
• Chinese trial participation: Lilly says Chinese patients took part in six of the eight global phase 3 studies of orforglipron ^[1].
• Local production: Lilly has said it plans to invest up to US$3 billion over ten years to expand its supply chain in China, including local production of oral solid medicines ^[1].

NBD pointed out that China's own 2024 obesity guideline defines overweight as a BMI of 24 to 28 and obesity as 28 or above, so a 27 threshold would leave out some people classed as overweight under Chinese guidance ^[2]. The final label wording will settle the exact scope; Lilly had not answered NBD's question on this when the article was published ^[2].

Where is orforglipron approved?

Orforglipron is approved in the US (April 2026), the UK (August 2026) and China (November 2026), and has a positive EU committee opinion awaiting a final European Commission decision ^[1][3][4][5]. Outside China it is sold as Foundayo ^[3][4][5].

United States

The FDA approved Foundayo on 1 April 2026 for adults with obesity, or overweight with at least one weight-related condition, alongside a reduced-calorie diet and more physical activity ^[3]. It was the first new molecular entity approved under the Commissioner's National Priority Voucher pilot programme, issued 50 days after filing, which the FDA called the fastest approval of a new molecular entity since 2002 ^[3].

United Kingdom

The MHRA authorised Foundayo on 10 August 2026 for weight management in adults with a BMI of 30 or above, or 27 to 30 with at least one weight-related condition, and for type 2 diabetes that is not well controlled ^[4]. The MHRA said it is a prescription-only medicine and is not currently available on the NHS, pending a NICE evaluation ^[4].

European Union

EMA's medicines committee, the CHMP, adopted a positive opinion on 15 October 2026 recommending a marketing authorisation for weight management and type 2 diabetes ^[5]. The legally binding decision rests with the European Commission and was still pending as of 13 November 2026 ^[5].

The table below summarises the status by regulator.

How much weight do people lose on orforglipron?

In the ATTAIN-1 trial, adults with obesity but no diabetes lost an average of 11.2% of their body weight over 72 weeks on the highest dose, compared with 2.1% on placebo ^[6]. The results were published in the New England Journal of Medicine in September 2025 ^[6].

• Who took part: 3,127 adults with obesity, without diabetes, randomised to one of three doses or placebo, all with diet and exercise advice ^[6].
• Average weight change at 72 weeks: −7.5%, −8.4% and −11.2% on the three doses, versus −2.1% on placebo ^[6].
• Larger losses: on the highest dose, 54.6% lost at least 10% of body weight and 36.0% lost at least 15%, versus 12.9% and 5.9% on placebo ^[6].
• Other measures: waist size, systolic blood pressure, triglycerides and non-HDL cholesterol improved compared with placebo ^[6].

Lilly's China release gives the same trial's result in kilograms: an average loss of 12.4 kg on the highest dose, with about 40% of patients losing more than 15% ^[1]. The release does not say which analysis its figures come from, and it uses kilograms rather than percentages, so they should not be compared directly with the NEJM percentages above.

A second trial, ATTAIN-2, tested orforglipron in more than 1,600 adults with obesity or overweight and type 2 diabetes ^[1]. Comparisons with injected drugs or with oral semaglutide across separate trials are not reliable, because the doses, durations and populations differ, a point NBD also made ^[2].

How is orforglipron different from Ozempic?

Orforglipron is a small, non-peptide molecule taken as a daily tablet without food or water restrictions, while Ozempic is semaglutide, a peptide drug injected once a week with a prefilled pen ^[1][2][4][8]. Both act on the GLP-1 receptor, mimicking a gut hormone that lowers blood sugar and reduces appetite ^[7].

• Molecule: orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist; NBD describes oral semaglutide as a peptide drug ^[1][2][6].
• How it is taken: once a day, at any time, with no food or water restrictions, the MHRA says ^[4]. Oral semaglutide must be taken on an empty stomach with limited water, NBD notes ^[2].
• US approvals: the FDA lists Ozempic (semaglutide) as approved in 2017 and Foundayo (orforglipron) in 2026 ^[7].

In the FDA's April 2026 announcement, Acting CDER Director Tracy Beth Høeg described orforglipron as a "GLP-1 receptor partial agonist pill which does not need to be taken on an empty stomach" ^[3].

The MHRA says Foundayo is a prescription-only medicine in the UK, and that all GLP-1 medicines are prescription-only ^[4]. Websites and social-media sellers offering orforglipron or "GLP-1 pills" without a prescription are outside these approvals; the warning signs of fake online shops are covered in Pouyam's guide Black Friday Scams: How to Spot Fake Stores, Phishing, Payment Fraud.

What are the side effects of orforglipron?

The most common side effects of orforglipron are gastrointestinal, such as nausea, vomiting, diarrhoea and constipation, and they were mostly mild to moderate in trials ^[3][5][6]. In ATTAIN-1, side effects led 5.3% to 10.3% of patients on orforglipron to stop treatment, compared with 2.7% on placebo ^[6].

Side effects listed by the FDA for Foundayo include nausea, constipation, diarrhoea, vomiting, indigestion, stomach pain, headache, fatigue, burping, reflux, gas and hair loss ^[3]. The FDA label also has warnings and precautions for ^[3]:

• inflammation of the pancreas (pancreatitis) and acute gallbladder disease;
• severe gastrointestinal reactions and acute kidney injury from dehydration;
• low blood sugar, allergic reactions, and diabetic retinopathy in people with type 2 diabetes;
• pulmonary aspiration during general anaesthesia or deep sedation.

The US label carries a boxed warning for thyroid C-cell tumours, and the drug should not be used by people with a personal or family history of medullary thyroid cancer or with MEN 2 syndrome ^[3]. It should not be combined with another GLP-1 drug ^[3].

The new eye warning

On 9 November 2026 the FDA required all GLP-1 drugs, with Foundayo named in its list, to add a warning about a potential increased risk of NAION, a rare optic-nerve condition that can cause sudden vision loss ^[7]. Lilly's China release says no liver safety signal was seen in the trials ^[1].

This is not medical advice. Decisions about your own treatment belong with a qualified clinician who knows your history.

What is confirmed and what is not?

The approvals in China, the US and the UK, the EU committee opinion, the trial results and the US safety warnings are confirmed; the Chinese label text, price and EU decision are not yet public ^[1][2][5]. As of 13 November 2026:

• Confirmed: NMPA approval on 12 November for adult weight management ^[1]; FDA approval on 1 April ^[3]; MHRA authorisation on 10 August ^[4]; CHMP positive opinion on 15 October ^[5].
• Reported, not in Lilly's release: the BMI 30, or 27 with a comorbidity, threshold in China, from NBD's reading of the NMPA notice ^[2].
• Pending: the European Commission decision, China's diabetes indication, and Chinese pricing and launch date ^[1][5].

AI chatbots often give out-of-date approval information for new drugs; how medical AI tools are tested and regulated is covered in AI in Healthcare: What It Can Do Today, Where It Fails and How It Is Regulated.